Galenicap SRL
Galenicap reported total assets of €1.47m at the end of the 2025 financial year (annual accounts filed with the NBB on 18 May 2026).
By total assets for 2025, Galenicap ranks among the 100 largest of the 327 companies in its sector (NACE 2110) in Belgium that filed accounts for that financial year. Largest companies in the sector →
The score of Galenicap shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2023 → 2025: Total assets +306 %
Accounts of the company itself (not consolidated).
The full file covers 3 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Galenicap's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 18 May 2026
- Year ended 31 Dec 2024filed on 07 May 2025
- Year ended 31 Dec 2023filed on 05 Jun 2024
Galenicap's financial analysis
- Solvency-17.6%sector median: 61.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Galenicap
Galenicap's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0782.712.794
- VAT number
- BE0782712794
- Peppol
- Registered · 0208:0782712794 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 28 Feb 2022
- Registered office
- 1050 Ixelles
- Latest accounts
- 2025 · filed on 18 May 2026
- Activity
- Manufacture of basic pharmaceutical products (NACE 21100)
Galenicap (SRL) has been based in Ixelles since 2022, active in: manufacture of basic pharmaceutical products. For 2025, it reports a net loss of 533,037 € and equity of −259,038 €; its revenue is not published. Its solvency stands at -17.6%, below the median of its sector (61.2%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Galenicap
Companies in the same business, of comparable size and area, outside its group.
- GRNR Invest Manufacture of basic pharmaceutical products Zemst · balance sheet €2.26m
- Pharma Chemicals France Manufacture of basic pharmaceutical products Braine-le-Château · balance sheet €1.08m
- XeroThera Europe Manufacture of basic pharmaceutical products Liège · balance sheet 820,359 €
- Plant Bio Technologies Manufacture of basic pharmaceutical products Ghent · balance sheet €1.04m
- OLYS Pharma Manufacture of pharmaceutical preparations La Hulpe · balance sheet €1.03m
- Equibor Manufacture of basic pharmaceutical products Manage · balance sheet €1.12m
- Temmune Therapeutics Manufacture of pharmaceutical preparations Mechelen · balance sheet €3.43m
- Asterion Research & Development Research and experimental development on natural sciences and engineering Ghent · balance sheet €2.31m
Frequently asked questions about Galenicap
What is the revenue of Galenicap?
Galenicap files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Galenicap?
In Belgium, the VAT number is the company number prefixed with BE: BE0782712794 for Galenicap, if the company is VAT-registered. Its company number (CBE) is 0782.712.794.
Where is the registered office of Galenicap?
According to the CBE register, the registered office of Galenicap is in 1050 Ixelles.
What is the equity of Galenicap?
At the close of the 2025 financial year, the equity of Galenicap amounts to -259,038 €, a solvency of -17.6% of total assets.
Who manages Galenicap?
The register lists 8 active mandates at Galenicap. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
How large is Galenicap within its sector?
By total assets for 2025, Galenicap ranks among the 100 largest of the 327 companies in its sector (NACE 2110) in Belgium that filed accounts for that financial year.
The full file of Galenicap
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →